上海市人民政府办公厅近日印发《上海市支持先进制造业转型升级三年行动方案（2026—2028年）》。 行动方案提出，到2028年，新增年产值10亿元以上制造业企业100家，累计超过600家，带动产业链新增 规上工业企业500家，规上制造业企业研发费用占营收比重显著提升。 上海市支持先进制造业转型升级三年行动方案（2026—2028年） 到2028年，新增年产值10亿元以上制造业企业100家，累计超过600家，带动产业链新增规上工业企业 500家，规上制造业企业研发费用占营收比重显著提升。 为加快构建以先进制造业为骨干的现代化产业体系，充分带动大中小企业协同融通发展，制定本行动方 案。 一、主要目标 二、实施结构调优升级行动 （一）优化提升传统优势产业。推动石化企业"去油增化"，布局新型功能材料；钢铁、有色金属企业做 强特种精品钢、做大轻合金；化妆品、食品等轻工企业以生态设计引领新消费，多出国货潮品。符合首 台（套）重大技术装备、首批次新材料条件的，按照最高不超过产品销售合同金额的30%给予支持，最 高不超过2000万元。（责任单位：市经济信息化委、各区政府） （二）加快先导产业战略引领。支持集成电路企业瞄准装备 ...

↓ ↓ 加入行业讨论群 ↓ ↓ | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 为落实《关于加快推进本市农业科技创新的实施意见》、《上海市促进科学仪器和科研试剂创新发展行动方案（2025 —2027年）》及《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若干措施》，助力提升上海相关 产业的创新策源能力，强化产业发展的知识产权支撑，上海市知识产权服务中心按照市知识产权局相关要求，建设完成 现代农业、科学仪器与科研试剂、细胞与基因治疗三大专题专利数据库，并于日前上线上海市知识产权信息服务平台。 三大专题专利数据库围绕本市相关产业发展需求，构建了科学细致、全面精准的技术分类。现代农业专题专利数据库聚 焦 农 业 机 械 化 与 智 能 化 、 生 物 农 业 与 育 种 、 数 字 农 业 、 绿 色 低 碳 农 业 四 大 技 术 主 题 ， 共 计 二 、 三 、 四 级 4 ...

Core Insights - Yantai aims to become a model city for green, low-carbon, and high-quality development, showcasing significant achievements in the economy and people's livelihoods by 2025 [1] Economic Growth - In 2023, Yantai became the first city in northern China to surpass a GDP of 1 trillion yuan, with a GDP growth of 6.4% in the first three quarters of 2025, leading among 27 trillion-yuan cities nationwide and 16 cities in the province [1] - From January to October, the city's industrial added value increased by 13.9%, and industrial technological transformation investment grew by 29.1%, indicating a simultaneous renewal of both incremental and stock growth [2] Industrial Transformation - Yantai has established a modern industrial structure categorized into three levels: - Level one focuses on optimizing five leading industry clusters: green chemicals, non-ferrous and precious metals, equipment manufacturing, deep processing of food, and modern services - Level two aims to cultivate five emerging industry clusters: electronic information, advanced structural materials, biomedicine, clean energy, and commercial aerospace - Level three anticipates future industry clusters in intelligent robotics, smart connected vehicles, low-altitude intelligent navigation, cell and gene therapy, and comprehensive utilization of hydrogen energy and LNG [2] Innovation Ecosystem - The transformation speed from laboratory to production line is a key measure of the effectiveness of Yantai's innovation ecosystem, exemplified by the Shandong Provincial Laboratory for Advanced Materials and Green Manufacturing, which has generated a sales increase of 1 billion yuan for partner companies and attracted 11 incubated companies [3] Green Development - Yantai has achieved a 20.9% cumulative reduction in energy intensity over the past three years and has met energy-saving and carbon reduction targets for 19 consecutive years [4] - The city has made significant strides in clean energy, being the first in Shandong to generate nuclear power and offshore wind power, and has established the largest tidal flat solar storage power station in the country [4] Social Impact - The integration of green low-carbon transformation with improvements in living standards has been a focus, with projects like the Haiyang nuclear heating project providing zero-carbon heating to hundreds of thousands of households [4] - The city has enhanced green travel and digital living, with smart city initiatives making services more accessible and improving commuting efficiency [4] Overall Transformation - The new quality productivity has led to a comprehensive, deep, and systematic evolution of Yantai, characterized by innovation-driven, green low-carbon, and people-centered development paths [5] - This transformation has resulted in higher development quality, better industrial structure, improved ecological environment, and enhanced public welfare, positioning Yantai as a more creative, competitive, and happier city [5]

Core Insights - Tianjin is leveraging technological innovation as a core engine for high-quality development, with the local securities regulatory authority actively guiding capital market resources to support the growth of tech enterprises [1][2][10] Group 1: Capital Market Support for Tech Innovation - The Tianjin Securities Regulatory Bureau has facilitated the listing of 14 new companies in the past five years, with nearly 80% being tech firms, showcasing the increasing "tech content" in Tianjin's capital market [2][10] - The successful listing of Danna Biotech on the Beijing Stock Exchange marks a significant milestone as it becomes the first company in the in vitro diagnostics sector to be listed there, highlighting the supportive role of the capital market in fostering tech innovation [2][10] - The Tianjin Securities Regulatory Bureau is enhancing its regulatory services to help tech companies adapt to market and regulatory requirements, ensuring steady progress in the capital market [3][10] Group 2: Financing Tools and Mechanisms - Various financing tools in the capital market are acting as accelerators for companies in Tianjin to optimize resource allocation and shift towards tech innovation [4][10] - Aima Technology successfully issued 2 billion yuan in convertible bonds, which not only provided long-term funding but also established a positive cycle of financing, R&D, and commercialization [4][5] - The issuance of "tech innovation" and "green" bonds by Chuangye Environmental and other companies illustrates the effectiveness of capital markets in meeting tech innovation needs [7][8] Group 3: Private Equity and Venture Capital - Private equity funds are playing a crucial role as "patient capital" for early-stage and growth-stage tech companies, helping them overcome R&D bottlenecks [9][10] - Huyuan Biotechnology, a leader in the CAR-T field, has benefited from private equity funding, which has supported its clinical applications and industrialization processes [9][10] Group 4: Collaborative Ecosystem Development - The Tianjin Securities Regulatory Bureau is working with multiple departments to optimize the regulatory environment and enhance the development ecosystem for tech companies [11][10] - A comprehensive policy framework has been established to support high-quality development in the capital market, including measures for venture capital and mergers and acquisitions [11][10] - The establishment of service platforms and databases aims to facilitate the growth of listed companies and improve the overall investment climate in Tianjin [11][10]

海河潮涌，创新潮生。在天津全力建设社会主义现代化大都市的征程中，科技创新正成为驱动高质量发 展的核心引擎。近年来，天津证监局在中国证监会和天津市委、市政府的领导下，联动多方力量，引导 资本市场各类资源精准滴灌科创沃土，通过支持企业发行上市、上市公司并购重组再融资、创新品种债 券发行、私募基金投资等多元路径，推动一批科创企业在政策扶持、金融助力、技术攻关的多重驱动下 成长壮大，在产业链供应链关键环节实现突破，不断书写了资本市场支持科技金融的天津篇章。 资本市场是科技创新的重要助推器，而高效的监管服务则是打通资本与科创对接壁垒的关键抓手。天津 证监局积极协同各方主动作为、精准发力，以全链条支持帮扶举措为辖区科技型企业用好资本市场铺路 搭桥。近五年，天津14家新上市公司中近八成为科技型企业，高新技术、专精特新上市公司达49家，家 数和总市值占比分别近七成、近八成，这组数据充分展现了天津资本市场"含科量"底色的日益浓厚。 科创债券引活水 精准滴灌研发路 科技创新离不开长期稳定的资金支持，尤其在研发攻坚的长跑赛道上，低成本、长周期的资金保障至关 重要。科创债新政落地以来，天津证监局协同相关政府部门积极行动，支持科创债通 ...

"并购六条"发布以来，上市公司在2025年掀起并购高潮，更具包容性的并购重组制度激活了资本市场新 生态。12月7日，在2025上证（巢湖）上市公司高质量发展大会的圆桌对话环节，多位上市公司创始 人、董事长围绕新质生产力领域的并购重组展开头脑风暴，共同研判2026年的产业并购新机遇、跨境并 购新挑战、并购交易新模式。 借力产业并购 实现行业领跑 "并购重组已成为提高上市公司质量的重要手段，目前，A股上市公司围绕新兴市场领域的并购重组活 跃度、包容性和灵活性正在全面提升。"中国科学技术大学科技商学院、管理学院执行院长叶强在主持 圆桌对话时表示。 当前，并购重组已成为A股公司实现跨越式发展的重要路径，也是企业筑就头部地位、抢抓产业机遇的 关键抓手，不断为高质量发展注入强劲动力。 "并购重组是企业实现外延式发展的重要路径之一。和元生物一直具有整合发展的理念，也体验过并购 重组带来的发展红利。"和元生物董事长潘讴东表示，公司在新三板转板科创板前，通过并购特定技术 领域的领先企业，成功跻身细胞与基因治疗领域头部阵营。 利元亨则是跨境并购的受益者。利元亨创始人、实控人卢家红介绍称，利元亨几年前收购了一家欧洲知 名装备企业的 ...

Core Insights - The article highlights the strategic development of Nansha District in Guangzhou as a key platform for comprehensive cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area, aiming to enhance its global presence [1][2]. Group 1: Innovation and Technology - Nansha is fostering innovation by collaborating with Shenzhen and Dongguan to establish a comprehensive national science center in the Greater Bay Area [1]. - The unveiling of the Hong Kong University of Science and Technology (Guangzhou) innovation and entrepreneurship community aims to facilitate the transformation of scientific achievements [1]. - The establishment of the Bay Area Artificial Intelligence Industry Innovation Alliance, initiated by Hong Kong University of Science and Technology and Huawei, signifies a push towards advanced technology development [1]. Group 2: Industrial Development - Nansha is accelerating the construction of a modern industrial system and nurturing emerging industries [1]. - The district has successfully conducted the first clinical application of cell and gene therapy for thalassemia in the country, showcasing advancements in future industries [1]. Group 3: Talent and Youth Engagement - A new professional title evaluation system for engineering talents from Hong Kong and Macao has been established, with 27 professionals receiving mainland titles [1]. - The creation of 19 youth innovation bases, including the Guangdong-Hong Kong-Macao (International) Youth Innovation Workshop, has led to the establishment of 2,670 enterprises and projects [1].

Core Viewpoint - Huabang Health (002004.SZ) is involved in the construction and operation of the Hebei Stem Cell Bank, focusing on the storage of newborn stem cells and adult immune cells, as well as clinical research and application transformation of stem cell products [1] Group 1 - Hebei Life Origin is the operator of the Hebei Stem Cell Bank, with its core business including the storage of newborn and adult immune cells [1] - Pruijin is primarily engaged in the research and development of innovative drugs for cell and gene therapy [1] - Puxin Biology mainly focuses on CDMO (Contract Development and Manufacturing Organization) services for cell and gene therapy drugs [1]

Focus Review - The hard technology sector, particularly energy storage and new energy technologies, is gaining significant attention, with companies like Xingchen New Energy completing over 300 million RMB in Series A financing [4][8]. - In biotechnology, cell and gene therapy (CGT) is emerging as a core area, exemplified by Weitao Bio's completion of over 100 million RMB in angel round financing [4][32]. - Local state-owned capital is actively supporting strategic emerging industries, as seen with Sengine Technology's nearly 100 million RMB in Pre-A and Pre-A+ financing [4][38]. Hard Technology - Xingchen New Energy completed over 300 million RMB in Series A financing, with investors including CITIC Construction Investment and various state-level funds [4][8]. - Wuxi Chip Field completed nearly 100 million RMB in A+ round financing, led by Woniu Capital [10]. - Chip manufacturer Chixin Semiconductor secured nearly 200 million RMB in Series A financing from multiple leading venture capital firms [19]. Biotechnology - Weitao Bio announced over 100 million RMB in angel round financing, led by Qiming Venture Partners [4][32]. - Yuesai Bio completed nearly 100 million RMB in A+ round strategic financing [35]. - Agile Medical completed several hundred million RMB in Series B financing, led by Mingxi Capital [27]. Internet/Enterprise Services - Sengine Technology completed nearly 100 million RMB in Pre-A and Pre-A+ financing, with participation from various state-owned and market-oriented investors [4][38]. - Zhongtong Cloud Warehouse Technology completed nearly 200 million RMB in Series A financing, led by CICC Capital [39]. - MatriQ, a neutral atom quantum computing company, announced the completion of seed round financing [42].

Core Insights - Cell and gene therapy (CGT) is recognized as a transformative biomedical technology aimed at treating diseases at their source, particularly in the ophthalmology sector, which is moving towards clinical application [1][2] - The industry is witnessing a strategic shift from focusing on rare genetic diseases to addressing common complex eye diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) [2][3] - The integration of capital into the CGT ecosystem is crucial for bridging the gap between laboratory breakthroughs and commercial implementation, with significant interest from investors [3][4] Industry Development - Advances in gene editing precision, standardization of stem cell therapies, and innovative delivery systems are propelling ophthalmic CGT from basic research to clinical application [2] - The market for ophthalmic CGT is expected to experience explosive growth due to increasing prevalence of eye diseases driven by aging populations and changing visual habits [2] Capital Empowerment - Capital is playing a pivotal role in connecting the innovation chain, industry chain, and funding chain, thereby accelerating the establishment of a comprehensive industrial ecosystem for ophthalmic CGT [3] - Over 40 CGT companies are reportedly queued for listing on the Hong Kong Stock Exchange in 2024, reflecting a 30% increase in valuation compared to the previous funding round, indicating strong market confidence in the sector [3] Company Strategies - He Eye Hospital Group is leveraging its comprehensive eye health ecosystem to focus on CGT, stem cell regenerative medicine, and smart ophthalmic equipment, aiming to integrate cutting-edge technology with healthcare data [4] - The company emphasizes an open ecosystem for CGT, fostering collaboration with other enterprises in technology and capital [4]